Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06049017
Other study ID # 77242113UCO2001
Secondary ID 77242113UCO20012
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 9, 2023
Est. completion date January 16, 2026

Study information

Verified date June 2024
Source Janssen Research & Development, LLC
Contact Study Contact
Phone 844-434-4210
Email Participate-In-This-Study@its.jnj.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date January 16, 2026
Est. primary completion date October 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed informed consent form 18 years of age or older - Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to screening - Moderately to severely active UC as per the modified Mayo score - Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol Exclusion Criteria: - Participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon - UC limited to rectum only or to less than (<) 15 centimeters (cm) of colon - Presence of a stoma - Presence or history of fistula - History of extensive colonic resection (example, <30 cm of colon remaining) - Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or clinical findings suggestive of Crohn's disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JNJ-77242113
JNJ-77242113 tablet will be administered orally.
Placebo
Placebo tablet will be administered orally.

Locations

Country Name City State
Argentina Cer Instituto Medico Buenos Aires
Argentina Gedyt - Consultorios Gastroenterologia Buenos Aires
Argentina CIPREC Ciudad Autonoma de Buenos Aires
Argentina Hospital Provincial del Centenario Rosario
Argentina Sanatorio 9 de Julio San Miguel de Tucuman
Australia Sunshine Coast University Hospital Birtinya
Australia Blacktown Hospital Blacktown
Australia Concord Repatriation General Hospital Concord
Australia Wollongong Private Hospital Wollongong
Belgium CHU Saint-Pierre Brussels
Belgium AZ Sint-Lucas Gent
Belgium Ghent University Hospital Gent
Belgium Universitair Ziekenhuis Leuven Leuven
Belgium Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman Liege
Belgium Vitaz Sint-Niklaas
Brazil UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu Botucatu
Brazil L2IP Instituto de Pesquisas Clinicas Brasília
Brazil CDC - Centro Digestivo de Curitiba Curitiba
Brazil Hospital de Clinicas de Porto Alegre - Hospital de Clinicas Porto Alegre
Brazil Pesquisare Saude Santo Andre
Brazil BR TRIALS-Ensaios Clinicos e Consultoria Ltda Sao Paulo
Brazil Instituto D Or de Pesquisa e Ensino Sao Paulo
Brazil INTEGRAL Pesquisa e Ensino Votuporanga
Canada Barrie GI Associates Barrie Ontario
Canada Gastroenterology and Internal Medicine Research Institute (GIRI) Edmonton Alberta
Canada London Health Sciences Centre London Ontario
Canada Centre Hospitalier de l'Universite de Montreal Montréal Quebec
Canada ABP Research Services Corp. Oakville Ontario
China The second Xiangya Hospital of Central South University Changsha
China Chongqing General Hospital Chongqing
China The First Affiliated Hospital Sun Yat sen University Guangzhou
China The Sixth Affiliated Hospital Sun Yat sen University Guangzhou
China Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou
China Qilu Hospital of Shandong University Jinan
China Lanzhou University Second Hospital Lan Zhou
China Nanjing Drum Tower Hospital Nan Jing Shi
China Shengjing Hospital Of China Medical University Shen Yang Shi
China Union Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan
China Wuxi People s Hospital Wuxi
China The Second Affiliated Hospital of Air Force Medical University - Tangdu Hospital Xi'An
Czechia Nemocnice Ceske Budejovice Ceske Budejovice
Czechia Gastroenterologie, s.r.o., Hradec Kralove Hradec Kralova
Czechia Hepato-gastroenterologie HK, s.r.o. Hradec Kralove
Czechia ISCARE a.s. Praha
Czechia Nemocnice Slany Slany
France CHRU Besancon Hopital Jean Minjoz Besancon Cedex
France APHP - Hopital Henri Mondor Creteil
France CHRU de Lille Hopital Claude Huriez Lille
France Clinique Ambroise Pare Neuilly-sur-Seine
France CHU de Nice Hopital de l Archet Nice
France CHU Nimes Hopital Caremeau Nimes Cedex
France APHP - Hopital Bichat - Claude Bernard Paris
France Hospices Civils de Lyon CHU Lyon Sud Pierre Benite
France CHU Saint Etienne Hopital Nord Saint Priest en Jarez
France CHU Toulouse - Hopital de Rangueil Toulouse
France CHU de Nancy_ Hopital Brabois Vandœuvre-les-Nancy
Germany Klinikum Augsburg Augsburg
Germany Krankenhaus Waldfriede Mitte Berlin
Germany Universitaetsklinikum Carl Gustav Carus TU Dresden Dresden
Germany Medizinische Hochschule Hannover Hannover
Germany Universitatsklinikum Schleswig Holstein Kiel Kiel
Germany Eugastro GmbH Leipzig
Germany Staedtisches Klinikum Lueneburg Lueneburg
Germany Gastroenterologische Gemeinschaftspraxis Minden Minden
Hungary Pannónia Magánorvosi Centrum Kft Budapest
Hungary Semmelweis Egyetem Budapest
Hungary Semmelweis Egyetem Budapest
Hungary Debreceni Egyetem Gasztroenterologiai Klinika Debrecen
Hungary Vasutegeszsegugyi Nonprofit Kozhasznu Kft Debrecen
Hungary Clinexpert Kft Gyongyos
India S. R. Kalla Memorial General Hospital Jaipur
India Midas Hospital Nagpur
India Govind Ballabh Pant Hospital New Delhi
India SIDS Hospital & Research Centre Surat
Italy Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano Milano
Italy Ospedale San Raffaele di Milano Milano
Italy Ospedale Sacro Cuore Don Calabria Negrar Di Valpolicella
Italy Azienda Ospedaliera San Camillo - Roma Roma
Italy Fondazione Policlinico Universitario A Gemelli IRCCS Roma
Italy Istituto Clinico Humanitas Rozzano
Italy Casa Sollievo della Sofferenza, IRCCS San Giovanni Rotondo
Japan Sai Clinic, Gastrointestinal and Protology Divisions Fujiidera-shi
Japan Hamamatsu University Hospital Hamamatsu
Japan Kagoshima IBD Gastroenterology Clinic Kagoshima
Japan Tsujinaka Hospital Kashiwanoha Kashiwa
Japan Aoyama Naika Clinic Kobe
Japan Japanese Red Cross Osaka Hospital Osaka
Japan Kinshukai Infusion Clinic Osaka
Japan Toho University Sakura Medical Center Sakura
Japan Sapporo Higashi Tokushukai Hospital Sapporo
Japan Sapporo Tokushukai Hospital Sapporo
Japan National Hospital Organization Shizuoka Medical Center Shimizu
Japan Tokyo Metropolitan Bokutoh Hospital Sumida ku
Japan Mie University Hospital Tsu
Japan Yokohama City University Medical Center Yokohama
Korea, Republic of Inje University Haeundae Paik Hospital Busan
Korea, Republic of Yeungnam University Hospital Daegu
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Kangbuk Samsung Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of The Catholic university of Korea, St. Vincent's Hospital Suwon-si
Malaysia Hospital Sultanah Aminah Johor Bahru
Malaysia Sultan Idris Shah Hospital Kajang
Malaysia University Malaya Medical Centre Kuala Lumpur
Poland Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy Bydgoszcz
Poland Centrum Medyczne Lukamed Chojnice
Poland Centrum Medyczne Plejady Krakow
Poland Centrum Medyczne Medyk Rzeszow
Poland Sonomed Sp. z o.o. Szczecin
Poland GASTROMED Sp. z o.o. Torun
Poland Bodyclinic Sp. z o.o. sp. k Warszawa
Poland Centralny Szpital Kliniczny Mswia Warszawa
Poland Medical Network Spolka z o.o. WIP Warsaw IBD Point Profesor Kierkus Warszawa
Poland Centrum Medyczne Oporow Wroclaw
Poland EMC Instytut Medyczny SA Wroclaw
Poland Melita Medical Sp. z o.o. Wroclaw
Romania S C Delta Health Care S R L Bucuresti
Romania Spital Memorial Bucuresti
Romania Digenio - Centrul Medical de Gastroenterologie, Hepatologie si Endoscopie Digestiva Cluj-Napoca
Romania Centrul Medical Valahia Ploiesti
Spain Hosp. Univ. Fundacion Alcorcon Alcorcon
Spain Hosp. Arquitecto Marcide Ferrol
Spain Hosp. de Cabuenes Gijon
Spain Hosp. Univ. La Paz Madrid
Spain Hosp. Univ. Pta. de Hierro Majadahonda Majadahonda
Spain Hosp. Clinico Univ. de Santiago Santiago de Compostela
Spain Hosp. Ntra. Sra. de Valme Sevilla
Spain Hosp. Virgen Macarena Sevilla
Spain Hosp. Clinico Univ. de Valencia Valencia
Spain Hosp. Univ. I Politecni La Fe Valencia
Spain Hosp. Alvaro Cunqueiro Vigo
Turkey Gazi University Medical Faculty Ankara
Turkey Uludag Universitesi Tip Fakultesi Hastanesi Bursa
Turkey Ege Universitesi Tip Fakultesi Izmir
Turkey Mersin University Medical Faculty Mersin
United Kingdom Fairfield General Hospital Bury
United Kingdom Addenbrookes Hospital Cambridge
United Kingdom Barts Health NHS Trust London
United Kingdom Guys St Thomas Hospital London
United Kingdom King s College Hospital London
United Kingdom St George's University Hospital NHS Foundation Trust London
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford
United Kingdom Whiston Hospital Prescot
United Kingdom Southampton University Hospital Southampton
United States Atlanta Gastroenterology Associates Atlanta Georgia
United States Mercy Medical Center Baltimore Maryland
United States Washington Gastroenterology, PLLC Bellevue Washington
United States University North Carolina at Chapel Hill Chapel Hill North Carolina
United States Atrium Health Charlotte North Carolina
United States Charlotte Gastroenterology and Hepatology, PLLC Charlotte North Carolina
United States Gastroenterology Associates of Tidewater Chesapeake Virginia
United States Peak Gastroenterology Associates Colorado Springs Colorado
United States DHAT Research Institute Garland Texas
United States Amel Med LLC Research Georgetown Texas
United States Gastroenterology Associates P.A. Greenville South Carolina
United States Accurate Clinical Research, Inc. Humble Texas
United States Ochsner Medical Center Jefferson Louisiana
United States I.H.S. Health. LLC Kissimmee Florida
United States Caprock Gastro Research Lubbock Texas
United States Tandem Clinical Research Marrero Louisiana
United States Gastroenterology of Southern Indiana New Albany Indiana
United States New York Gastroenterology Associates New York New York
United States Hoag Memorial Hospital Newport Beach California
United States DiGiovanna Institute for Medical Education & Research North Massapequa New York
United States Care Access Research, Ogden Ogden Utah
United States Digestive Disease Specialists Inc Oklahoma City Oklahoma
United States Clinnova Research Orange California
United States Endoscopic Research Inc Orlando Florida
United States Mayo Clinic Rochester Rochester Minnesota
United States Southern Star Research Institute, LLC San Antonio Texas
United States Medical Associates Research Group, Inc. San Diego California
United States Washington Gastroenterology, PLLC Tacoma Washington
United States GCP Clinical Research Tampa Florida
United States Cotton O'Neil Digestive Health Center Topeka Kansas
United States Tyler Research Institute, LLC Tyler Texas
United States Northshore Gastroenterology Research, LLC Westlake Ohio

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Brazil,  Canada,  China,  Czechia,  France,  Germany,  Hungary,  India,  Italy,  Japan,  Korea, Republic of,  Malaysia,  Poland,  Romania,  Spain,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Clinical Response at Week 12 Clinical response is defined as decrease from baseline in the modified Mayo score by greater than or equal to (>=) 30 percent (%) and >=2 points, with either a >=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. Week 12
Secondary Percentage of Participants with Clinical Remission at Week 12 Clinical remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1. Week 12
Secondary Percentage of Participants with Symptomatic Remission at Week 12 Symptomatic remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, and a rectal bleeding subscore of 0. Week 12
Secondary Percentage of Participants with Endoscopic Improvement at Week 12 Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Week 12
Secondary Percentage of Participants with Histologic-endoscopic Mucosal Improvement at Week 12 Histologic-endoscopic mucosal improvement is defined as a combination of histologic remission and endoscopic improvement. Histologic remission and endoscopic improvement are based on the histologic grading and the Mayo endoscopy subscore. Week 12
Secondary Percentage of Participants with Adverse Events (AE) and Serious Adverse Evets (SAEs) An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. Up to Week 76
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Completed NCT03494764 - Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares Phase 2
Recruiting NCT03937609 - TITRATE (inducTIon for acuTe ulceRATivE Colitis) Phase 4
Completed NCT00503243 - Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis Phase 3
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed NCT02537210 - Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis N/A
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT00488631 - An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT00928681 - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis Phase 1
Recruiting NCT05242484 - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2
Completed NCT01036022 - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis Phase 2
Recruiting NCT03841045 - Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Active, not recruiting NCT05528510 - A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT02825914 - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) N/A
Completed NCT04567628 - Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Withdrawn NCT05999708 - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants Phase 1
Recruiting NCT05611671 - A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC Phase 2
Active, not recruiting NCT03596645 - A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03648541 - BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis Phase 2
Completed NCT02840721 - Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. Phase 2